1. We have studied the plasma lipoprotein abnormalities in obstructive jaundice to test the hypothesis that the abnormalities would correlate with plasma lecithin--cholesterol acyltransferase activity. 2. Very-low-density lipoproteins (VLDL) were normal in composition and had a normal pre-beta electrophoretic mobility when lecithin--cholesterol acyltransferase activity was high. When it was low VLDL had abnormal composition and ran in the beta position. 3. With high lecithin--cholesterol acyltransferase activity, low-density lipoprotein (LDL) was normal and cholestatic LDL (LP-X) was not found. With low lecithin--cholesterol acyltransferase activity up to three LDL fractions were found: (i) large triglyceride-rich particles, (ii) LP-X and (iii) a triglyceride-rich cholesteryl ester-poor particle of normal dimensions. 4. High-density lipoprotein (HDL) concentrations correlated with lecithin--cholesterol acyltransferase activity and HDL were normal in composition and electron-microscopic appearance when the activity was high. When lecithin--cholesterol acyltransferase activity was low HDL was abnormal in composition and 'stacked discs' were seen on electron microscopy as well as normal spherical particles. 5. These results suggest that low lecithin-cholesterol acyltransferase activity may cause at least some of the lipoprotein changes of obstructive jaundice.
21133 Background: : Aim of this study is to evaluate the diagnostic value of serum levels of vascular endothelial growth factor ( VEGF ), basic fibroblast growth factor ( bFGF ) and Endostatin in patients with primary hepatocellular carcinoma ( PHC ) and in patients with metastatic liver disease ( MLD ). Methods: Eighty participants were included in this study and divided into three groups. Exclusion criteria were history of myocardial infraction, stroke, diabetic retinopathy, rheumatoid arthritis, psoriatic arthritis, pregnancy, trauma and recent surgical treatment. In group A were included 20 normal controls (NC), in group B 30 patients with PHC and in group C 30 patients with MLD. The concentrations of VEGF, bFGF and Endostatin in serum were measured by using enzyme like immunosorbent assay kits (Quantikine R&D systems Inc., Mineapolis.MN). Results: Results are shown in table . In patients with PHC there was a positive correlation between the serum level of VEGF and tumor size (r=0.517, p=0.08), between the serum level of VEGF and platelets number (r=0.573, p=0.003) and between the serum level of VEGF and the serum level of a-fetoprotein (r=0.478, p=0.029). In patients with PHC sensitivity of VEGF, bFGF and Endostatin was found 60%, 54% and 23% respectively. In patients with MLD sensitivity of VEGF, bFGF and Endostatin was found 73%, 73% and 27.5% respectively. However, both in patients with PHC and with MLD specificity of VEGF, bFGF and Endostatin were found 95%, 95% and 100% respectively. Conclusions: Angiogenic factors VEGF, bFGF and Endostatin can distinguish normal controls from patients with liver cancer. Serum levels of VEGF are related to the size of the tumor in patients with PHC. Serum VEGF, bFGF and Endostatin could be useful tumor markers in the diagnosis of PHC and MLD because of their high specificity. The significant correlation of VEGF with a- fetoprotein indicates its importance as a marker in diagnosis of PHC. [Table: see text] No significant financial relationships to disclose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.